|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Albain K et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). San Antonio Breast Cancer Symposium 2007;Abstract 10.
Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on
Phase III Intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004;Abstract 37.
Goldstein LJ et al. Prognostic utility of 21-gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of Intergroup Trial E2197. Proc ASCO 2007;Abstract 526.
Kamal AH et al. How well do standard prognostic criteria predict Oncotype DX (ODX) scores? Proc ASCO 2007;Abstract 576.
Lo SS et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. Proc ASCO 2007;Abstract 577.
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
 |
 |
EDITOR'S NOTE
San Antonio adventure, 2007
Neil Love, MD
- Select publications
INTERVIEWS
Stephen E Jones, MD
- Select publications
Sir Richard Peto, FRS
- Select publications
Kathy S Albain, MD
- Select publications
Roundtable Discussion
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Nancy U Lin, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
